Abrocitinib is a Janus kinase (JAK)1 inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of haematopoiesis and immune cell function. It is used for the treatment of moderate-to-severe atopic dermatitis in adults.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Abrocitinib is the active ingredient of these drugs:
Estonia Finland Ireland Poland United Kingdom
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):